IRON CHELATION AND GPX4 STABILIZATION

A Comprehensive Analysis of Ferroptosis Pharmacology in the Context of Neurodegenerative Therapeutics

A Synthetic Monograph in the Organic Network Synthesis Methodology
Bioenergetic Pharmacology Series · Volume III

Ben Gustafsson

Prepared under the ONS Methodology

AdultCognitiveDisease.com

June 2026

First Edition

Third and concluding volume of the ONS Bioenergetic Pharmacology series. Companion to Volume I (Pharmacological Modulation of Mitochondrial ATP Synthase) and Volume II (NAD^+ Restoration and CD38 Inhibition). Integrates the Bush, Stockwell, Conrad, Maher, and Kenkhuis research programs into a single analytical framework on the pharmacology of ferroptosis prevention.

“Iron is the substrate of every electron transfer in the brain, and the substrate of every Fenton reaction that destroys the brain. The pharmacological problem is the compartment, not the quantity.”

— After Bush, *Iron on Trial*, 2025

For the laboratories of the Florey Institute and Columbia, and for the patients whose membranes have already begun to fail.

THE ONS BIOENERGETIC PHARMACOLOGY SERIES

I. Pharmacological Modulation of ATP Synthase

II. NAD^+ Restoration and CD38 Inhibition

III. Iron Chelation and GPX4 Stabilization ☐ this volume

Each volume of the Bioenergetic Pharmacology series examines a single rate-limiting catalytic node in the mitochondrial-autophagic axis and the medicinal-chemistry pipelines that engage it. The series is the translational arm of the Collapse Trilogy: where the trilogy mapped the circuit, cellular, and substrate failures, the pharmacology series examines the pharmacological wedges by which those failures can be prevented, slowed, or in principle reversed.

Abstract

Ferroptosis — the iron-catalyzed, lipid-peroxidation-driven, regulated form of non-apoptotic cell death formally defined by Dixon, Stockwell, and colleagues in 2012 — has emerged in the last fifteen years as one of the principal terminal cell-death modalities in age-associated neurodegeneration. The aging brain accumulates iron disproportionately in the hippocampus, substantia nigra, and basal ganglia; this iron drives the Fenton chemistry that generates membrane lipid hydroperoxides; the antioxidant enzyme glutathione peroxidase 4 (GPX4) must keep pace with the hydroperoxide flux, and when it cannot, ferroptotic cell death ensues.

This monograph evaluates the two principal pharmacological strategies that have emerged from this mechanistic understanding. The *iron-compartmentalization strategy* uses chelators to redistribute the brain's labile iron pool from cytosolic and lysosomal compartments where it catalyzes lipid peroxidation into ferritin-bound or extracellularly excreted forms where it does not. The *GPX4 stabilization strategy* preserves or restores the activity of the glutathione-dependent lipid hydroperoxidase that prevents ferroptotic cell death, operating through selenium supplementation, small molecule GPX4 stabilizers, lipid-soluble radical-trapping antioxidants (ferrostatin-1, liproxstatin-1), and the parallel FSP1–CoQ_{10} pathway.

The monograph develops these strategies through six analytical chapters, analyzes the disappointing 2024 deferiprone Phase II trial that has shaped contemporary thinking, situates the analysis within the Collapse Trilogy framework and the broader four-component bioenergetic regimen developed across Volumes I–III, and concludes with seven falsifiable experimental predictions. The argument advanced is that the ferroptosis axis is the *terminal substrate* into which upstream bioenergetic failures express themselves — and that pharmacological intervention against ferroptosis is therefore the rate-limiting variable for preserving cellular viability once the upstream bioenergetic threshold has been crossed.

Keywords: ferroptosis, GPX4, iron chelation, deferiprone, selenium, APP-ferroportin axis, PSEN1-Notch-LRP8, FSP1, CoQ_{10}, liproxstatin, ferrostatin, Alzheimer's disease

Note on Sources

This monograph is the third and concluding volume of the ONS Bioenergetic Pharmacology series. It integrates the Bush, Stockwell, Conrad, Maher, and Kenkhuis

research programs into a single analytical narrative on the pharmacology of ferroptosis prevention. Where the prevailing literature is unsettled — particularly around the interpretation of the negative deferiprone Phase II trial in Alzheimer's disease and the comparative role of iron chelation versus GPX4 stabilization — sources are explicitly weighted. The monograph should be read as a synthetic review under the Organic Network Synthesis methodology, not a primary experimental report.

Contents

Executive Summary

Ferroptosis — the iron-catalyzed, lipid-peroxidation-driven, regulated form of non-apoptotic cell death formally defined by Dixon, Stockwell, and colleagues in 2012 — has emerged in the last fifteen years as one of the principal terminal cell-death modalities in age-associated neurodegeneration. The aging brain accumulates iron disproportionately in the hippocampus, substantia nigra, and basal ganglia; this iron drives the Fenton chemistry that generates membrane lipid hydroperoxides; the antioxidant enzyme glutathione peroxidase 4 (GPX4) must keep pace with the hydroperoxide flux, and when it cannot, ferroptotic cell death ensues.

This monograph evaluates the two principal pharmacological strategies that have emerged from this mechanistic understanding. The *iron-compartmentalization strategy* uses chelators to redistribute the brain's labile iron pool from cytosolic and lysosomal compartments where it catalyzes lipid peroxidation into ferritin-bound or extracellularly excreted forms where it does not. The *GPX4 stabilization strategy* preserves or restores the activity of the glutathione-dependent lipid hydroperoxidase that prevents ferroptotic cell death, operating through selenium supplementation, small molecule GPX4 stabilizers, lipid-soluble radical-trapping antioxidants (ferrostatin-1, liproxstatin-1), and the parallel FSP1–CoQ_{10} pathway.

The two strategies are mechanistically complementary in the same upstream-versus-downstream sense developed in Volumes I and II of this series: chelation reduces the substrate flux into the Fenton reaction, while GPX4 stabilization preserves the cellular defense against the resulting lipid hydroperoxides. The monograph develops these strategies through six analytical chapters, analyzes in detail the disappointing 2024 deferiprone Phase II trial that has reshaped contemporary thinking about brain iron pharmacology, and concludes with seven falsifiable experimental predictions and a concluding synthesis of the Bioenergetic Pharmacology series.

Chapter I

Ferroptosis and the Iron Problem in the Aging Brain

1.1 The Research Problem

The conventional taxonomy of cell death distinguished, for most of the twentieth century, between apoptosis (a regulated, caspase-dependent, non-inflammatory program) and necrosis (an unregulated, energy-failure-driven, inflammatory collapse). The discovery, formalized by Dixon and Stockwell in 2012, of a *third* canonical modality — ferroptosis — disrupted this taxonomy and opened a substantial new therapeutic landscape. Ferroptosis is regulated (it has a defined molecular machinery), iron-dependent (the catalysis runs through Fenton chemistry), and lipid-peroxidation-driven (its substrate is polyunsaturated fatty acid esters in membrane phospholipids).

Two parallel lines of evidence have established ferroptosis as a major proximate driver of neuronal loss in age-associated neurodegeneration. The first is Ashley Bush's iron-centered reframing of Alzheimer's disease, which argues that age-related brain iron accumulation is the proximate causal variable from which much of the canonical AD pathology emerges downstream. The second is Pamela Maher's oxytosis/ferroptosis framework, which maps the biochemical cascade from glutathione depletion through GPX4 inactivation, 12/15-lipoxygenase activation, and 4-HNE generation to the lysosomal v-ATPase poisoning that connects ferroptotic stress to autophagic-lysosomal collapse.

The therapeutic implication is that pharmacological agents capable of suppressing the iron flux into Fenton chemistry (chelators) or of stabilizing the GPX4 defense (selenium, small molecule stabilizers, lipid-soluble radical traps, FSP1-CoQ_{10} mimetics) constitute a class of disease-modifying interventions whose target is the terminal cell-death substrate rather than upstream proteinopathy. This class is mechanistically complementary to the ATP synthase modulators of Volume I and the NAD^+/CD38 axis

of Volume II.

1.2 The Ferroptotic Pathway: Definition and Molecular Machinery

The ferroptotic pathway operates through four interacting molecular systems. *The glutathione–GPX4 axis* is the principal cellular defense: System X_c^- imports cystine in exchange for glutamate; cystine is reduced to cysteine, the rate-limiting substrate for glutathione (GSH) synthesis; GPX4 uses GSH to reduce phospholipid hydroperoxides to phospholipid alcohols. GPX4 is the only enzyme capable of reducing *membrane-integrated* lipid peroxides — the substrates that drive ferroptotic membrane disruption.

Iron-catalyzed Fenton chemistry is the principal driver of non-enzymatic lipid peroxidation. Labile ferrous iron reacts with hydrogen peroxide to generate hydroxyl radicals that attack PUFAs in membranes, initiating a chain reaction. *Lipoxygenase-mediated peroxidation* contributes the principal enzymatic arm: 12/15-lipoxygenase oxidizes arachidonic acid-containing phosphatidylethanolamine. *The FSP1–CoQ_{10} parallel pathway* provides a GPX4-independent defense: FSP1 reduces CoQ_{10} to ubiquinol, which acts as a lipid-soluble radical-trapping antioxidant in membranes independently of GPX4.

1.3 The Brain Iron Paradox

Iron is uniquely paradoxical among the cellular trace metals. It is essential — required as a co-factor for hemoglobin, the iron-sulfur clusters of Complexes I, II, and III of the electron transport chain, the heme of Complex IV, and the active site of multiple aromatic-amino-acid hydroxylases. It is toxic — the same redox versatility that makes iron useful as an electron carrier makes it dangerous as a generator of hydroxyl radicals through Fenton chemistry. And it accumulates with age — the adult human brain accumulates approximately one milligram of iron per year through middle age.

The paradox is therapeutic as well as biological. Pan-iron depletion — the strategy that worked spectacularly for transfusional iron overload — fails in neurodegeneration because the essential roles of iron are not substitutable. The pharmacological target is therefore not iron content but iron *compartmentalization*: redistributing the labile, Fenton-active iron pool from cytosolic and lysosomal compartments into ferritin-bound

or extracellularly excreted forms. This reframing is the principal lesson of the Bush program of the last decade.

1.4 The Bush Reframe: Iron Compartmentalization vs Depletion

Ashley Bush and colleagues at the Florey Institute have developed the most rigorous iron-centered framework for AD. The framework rests on several interlocking claims. *First*, brain iron accumulates with age and further in AD-vulnerable regions, with the magnitude tracking cognitive decline more closely than amyloid burden (Ayton et al., 2020). *Second*, APP and tau both bind iron and stabilize ferroportin, the sole cellular iron exporter; familial AD mutations that impair this function cause iron retention. *Third*, the PSEN1-Notch-LRP8-GPX4 signaling axis provides a direct genetic-mechanistic link from familial AD mutations to ferroptotic vulnerability. *Fourth*, both amyloid plaques and tau tangles may function as *compensatory sinks* that sequester redox-active iron and toxic lipid aldehydes.

The Bush framework leads to a specific therapeutic prediction: pan-iron-depleting chelation will fail because it strips iron from essential cellular processes without preferentially addressing the labile iron pool that drives ferroptosis. The therapeutic target is *selective* compartmentalization. This prediction was operationalized in the 2024 deferiprone Phase II trial, which demonstrated brain iron reduction but produced a *worsening* of cognitive decline relative to placebo — a result that has reshaped contemporary thinking.

1.5 Significance

The reframing of ferroptosis as the terminal cell-death substrate of upstream bioenergetic decline carries four significant implications. *First*, it identifies a target class — iron chelators and GPX4 stabilizers — that is mechanistically downstream of the bioenergetic interventions examined in Volumes I and II and may therefore be required for full disease modification. *Second*, it accounts for the regional vulnerability of neurodegeneration. *Third*, it links the ferroptotic axis to the Volume II NAD^+ axis through the NADPH-GSH-GPX4 regeneration cascade. *Fourth*, it provides a mechanistic explanation for the puzzling failure of classical antioxidant therapy in AD trials: classical antioxidants are cytosolic and do not address membrane-integrated lipid peroxidation, which only GPX4 can resolve.

1.6 Scope and Method

This monograph is a synthetic review under the ONS methodology, integrating ten research programs into a unified analytical framework. The work is structured around the two principal pharmacological strategies and the integration of the resulting analysis with the broader four-component bioenergetic regimen developed across Volumes I–III. Citations follow APA 7th edition.

Chapter II

Iron Biology in the Aging Brain

2.1 Iron Uptake and Homeostasis

The adult brain acquires iron through transferrin receptor (TfR1)–mediated endocytosis at the blood-brain barrier. Iron-loaded transferrin binds TfR1; the complex is internalized into endosomes; acidic pH releases iron from transferrin; iron is exported through DMT1 on the abluminal surface. The parenchymal iron is then distributed across neuronal, astrocytic, oligodendrocyte, and microglial pools.

The total brain iron content rises monotonically through the first six decades of life, with the accumulation concentrated in specific cell types and regions. Oligodendrocytes accumulate the largest iron pool (reflecting iron's role in myelination); microglia accumulate iron particularly in association with inflammation and amyloid pathology; and substantia nigra dopaminergic neurons accumulate the highest neuronal iron content of any neuron in the brain. The regional pattern closely tracks the regional vulnerability of neurodegeneration: substantia nigra in Parkinson's, hippocampus and parietal cortex in Alzheimer's, basal ganglia in Huntington's, motor cortex and spinal cord in ALS.

2.2 Ferritin, Ferroportin, and Hepcidin

Three proteins govern cellular iron storage and export. *Ferritin* is the principal iron-storage protein, a 24-subunit cage that sequesters up to 4,500 iron atoms in a non-reactive ferric form. *Ferroportin* is the sole cellular iron exporter, the principal regulator of cellular iron retention. *Hepcidin* is the systemic iron-regulatory hormone, secreted by the liver, that binds ferroportin and triggers its internalization. High hepcidin traps iron inside cells; low hepcidin allows iron export.

The APP-ferroportin connection — established by Duce, Bush, and colleagues in 2010 — placed APP biology at the center of brain iron homeostasis. APP physically associates with ferroportin at the cell surface and stabilizes the exporter against

hepcidin-mediated degradation; APP cleavage or familial AD mutations that impair APP function therefore impair iron export, raise intracellular iron, and elevate ferroptotic vulnerability. This finding reinterprets AD-associated APP biology as fundamentally an iron-handling biology.

2.3 The Labile Iron Pool and Fenton Chemistry

The cellular iron pool is not homogeneous. Most cellular iron is bound to ferritin (storage), to functional iron-sulfur clusters, to heme, or to iron-binding regulatory proteins. A small fraction — the "labile iron pool" — is loosely bound to low-molecular-weight cytosolic ligands and is available for both incorporation into new iron-containing proteins and for Fenton-catalyzed generation of hydroxyl radicals. The labile pool is estimated at approximately 1–10 μM in healthy cells and rises substantially under oxidative stress.

The Fenton reaction operates as $Fe^{2+} + H_2O_2 \rightarrow Fe^{3+} + {\bullet}OH + OH^-$, with Fe^{3+} subsequently reduced back to Fe^{2+} by cellular reductants. The reaction produces hydroxyl radicals — the most reactive of the physiologically relevant ROS — which attack PUFAs in membranes to generate lipid radicals that propagate through chain reactions. The labile iron pool is therefore the principal substrate of the Fenton chemistry that drives ferroptosis. Pharmacological agents that reduce the labile pool without stripping iron from functional bound pools are the principal upstream intervention.

2.4 Plaques and Tangles as Iron Sinks

Among the most consequential reframings of canonical AD pathology has been the recognition that amyloid plaques and tau tangles may function as *iron sinks*. Amyloid-β binds iron with high affinity, and aged plaques accumulate substantial iron stores. Hyperphosphorylated tau binds iron at multiple sites. The implication is that plaques and tangles may, in early stages, serve a *protective* function by sequestering redox-active iron. The pathological phenotype may emerge only when the iron-binding capacity of the aggregate is overwhelmed.

This reframing has two important pharmacological consequences. *First*, amyloid clearance therapies (lecanemab, donanemab) may *paradoxically* mobilize sequestered iron back into the labile pool, producing transient ferroptotic stress that contributes to

the inflammatory adverse events characteristic of the class. *Second*, iron chelation co-administered with amyloid clearance would mitigate the ferroptotic-stress arm of the adverse event profile and may improve cognitive benefit. This combination has not been tested clinically.

Chapter III

Iron Chelation

Strategy, Compounds, and the Deferiprone Lesson

3.1 The Chelation Strategy and Its Trade-offs

Iron chelation was developed initially for transfusional iron overload in patients with hemoglobinopathies, where chronic transfusion produces systemic iron accumulation that, untreated, results in fatal cardiomyopathy and hepatic failure. The chelators developed for this indication — deferoxamine (1968), deferiprone (1995), and deferasirox (2005) — were designed to bind iron with high affinity, traverse the membrane into iron-loaded cells, and excrete iron through urine or feces. The clinical record in transfusional iron overload is excellent; the extrapolation to the aging brain is more difficult.

The principal trade-offs of brain iron chelation are three. *First*, iron is essential for many cellular functions; pan-iron-depleting chelation can produce anemia, depressed Complex I activity, dopamine-synthesis impairment, and other adverse effects. *Second*, the chelator must cross the BBB to reach brain iron pools; many otherwise effective chelators (deferoxamine, deferasirox) are too polar or too large. *Third*, the chelator must preferentially bind labile iron rather than functional iron — a structural selectivity property difficult to engineer.

3.2 Deferoxamine: The Original

Deferoxamine (Desferal) was isolated from *Streptomyces pilosus* in the 1950s and developed as the first clinical iron chelator. It binds iron with high affinity but is too polar to cross the BBB in therapeutically meaningful quantities and requires parenteral administration. A small AD trial of deferoxamine in 1991 (Crapper McLachlan et al.) reported modest slowing of cognitive decline over 24 months, but the route of administration and the substantial side-effect profile prevented broader development. The Crapper McLachlan trial remains historically important as the first demonstration that iron chelation could slow AD cognitive decline.

3.3 Deferiprone: The Brain-Penetrant Chelator

Deferiprone (Ferriprox) is a small, lipophilic, orally bioavailable iron chelator developed in the 1990s. It crosses the BBB efficiently, binds labile iron with moderate affinity, and excretes iron-deferiprone complexes through urine. The brain penetrance made it the obvious candidate for clinical testing in neurodegeneration, and several Phase II trials in AD, PD, and Friedreich's ataxia were initiated in the 2010s.

The most rigorously conducted trial — and the one whose results have most strongly shaped the field — was the Deferiprone for Alzheimer's Disease (Devine) Phase II study, conducted by the Bush group with collaboration from multiple academic centers. The trial enrolled 171 patients with mild-to-moderate AD, randomized to deferiprone or placebo over 12 months, with MRI iron-content endpoints and ADAS-Cog cognitive endpoints. The trial demonstrated successful brain iron reduction (~25% decrease in hippocampal iron) but produced a *worsening* of cognitive decline relative to placebo on the ADAS-Cog primary endpoint. The result was presented in 2024 and published in 2025; it has substantially altered the field's thinking.

3.4 “Iron on Trial”: The Bush Reinterpretation

Bush’s response to the negative deferiprone trial — published as a *Brain* review titled “Iron on Trial” — has reframed the entire field’s approach to iron pharmacology. The principal argument is that pan-iron-depleting chelation cannot succeed in AD because iron is required for multiple essential cellular functions that the chelator cannot distinguish from its labile-pool target. The trial reduced both the harmful labile pool *and* the essential bound pools, with the latter producing functional deficits that offset or exceeded the benefit of reducing the former. The therapeutic target is not iron depletion but iron *compartmentalization*.

This reframing has three pharmacological implications. *First*, the next generation of brain iron pharmacology must be more selective: compounds that preferentially address the labile pool without depleting bound pools. *Second*, GPX4 stabilization may be a more tractable therapeutic strategy than iron chelation in the near term, because it operates downstream of iron flux without requiring difficult selectivity engineering. *Third*, the combination of selective compartmentalization with GPX4 stabilization — attacking the ferroptotic cascade from both upstream and downstream — is likely to be more effective than either alone.

3.5 Beyond Deferiprone: Selective Compartmentalization Strategies

The post-deferiprone iron pharmacology landscape includes several emerging strategies. *Siderophore mimetics* — synthetic small molecules modeled on bacterial iron-scavenging compounds — bind labile iron with high selectivity. *Ferritin-stabilizing compounds* increase ferritin’s iron-binding capacity. *Ferroportin modulators* either upregulate ferroportin expression or suppress hepcidin. *Heme oxygenase modulators* engage the catabolic pathway through which heme is converted to biliverdin, iron, and carbon monoxide, with biliverdin and CO contributing to antioxidant defense. Each addresses a different arm of the iron-handling system.

3.6 The Conrad–Bush Convergence

Marcus Conrad and Ashley Bush, working independently in Munich and Melbourne, have converged on a shared analytical framework in the post-deferiprone period. The shared framework holds that ferroptosis in neurodegeneration is best understood as a *threshold* phenomenon: cells maintain ferroptotic resistance through a balance of iron flux, lipid PUFA composition, GPX4 activity, and FSP1-CoQ_{10} defense, and ferroptotic death occurs when this balance crosses a threshold. The implication is that *multi-arm* intervention is more effective than single-arm intervention, because the threshold can be displaced by modest interventions across several arms more easily than by large interventions on any single arm. The Conrad-Bush convergence is the principal intellectual basis for the combination-therapy hypothesis advanced in §5 and §6.

Chapter IV

GPX4 Stabilization

Selenium, Small Molecules, and the FSP1 Parallel

4.1 GPX4: Structure, Mechanism, Regulation

Glutathione peroxidase 4 is the single most consequential anti-ferroptotic defense in the cell. It is a member of the eight-protein glutathione peroxidase family but is functionally distinct in its ability to reduce *membrane-integrated* lipid hydroperoxides: GPX1–3 reduce only free hydrogen peroxide and small-molecule hydroperoxides, while GPX4 alone can resolve the phospholipid hydroperoxides that form in the membrane bilayer. This distinction makes GPX4 the only enzyme capable of preventing the chain-reaction propagation of membrane lipid peroxidation, which is the proximate driver of ferroptotic membrane disruption.

GPX4 is a selenoprotein: its active site contains a selenocysteine residue (Sec46) that performs the catalytic reduction. The selenocysteine is biosynthesized through a tRNA-dependent mechanism that requires dietary selenium, the SECIS element in the GPX4 mRNA, and a battery of selenoprotein-biosynthesis factors. Selenium availability is therefore a rate-limiting upstream variable. GPX4 catalyzes the reduction of phospholipid hydroperoxide to phospholipid alcohol using two molecules of GSH; turnover is fast (~1,000 per second), and the rate-limiting variable in most contexts is GSH availability. GSH is regenerated by glutathione reductase using NADPH, linking GPX4 activity to NADPH/$NADP^+$ status, NAD^+/NADH status (Volume II), and ultimately the mitochondrial energy state (Volume I).

4.2 The Selenium Dependency

Selenium is among the most rate-limiting trace nutrients for ferroptotic defense. Dietary selenium deficiency reduces brain GPX4 activity within weeks. The relationship is not linear: GPX4 activity rises with selenium status up to a saturation point at approximately 90–100 μg/L plasma selenium. Many populations — particularly in Northern Europe and parts of North America — have plasma selenium in the 70–90 μg/L range, suggesting that selenium supplementation may produce measurable elevation.

The PSEN1-Notch-LRP8-GPX4 axis identified by the Bush group provides the specific mechanistic link from familial AD mutations to selenium-dependent GPX4 function. PSEN1 processes Notch; Notch intracellular domain regulates LRP8 transcription; LRP8 mediates selenium uptake as selenoprotein P; LRP8 expression therefore controls selenium delivery to neurons. PSEN1 mutations that impair γ-secretase reduce LRP8 expression, reduce selenium uptake, and elevate ferroptotic vulnerability. The pharmacological implication is that selenium supplementation in PSEN1 carriers may produce measurable elevation in GPX4 activity.

4.3 Small-Molecule GPX4 Stabilizers

Beyond selenium supplementation, a class of small-molecule GPX4 stabilizers is in development. These compounds bind GPX4 at allosteric sites and stabilize the active conformation against the proteasomal degradation that limits GPX4 half-life. The class is at an early stage of development; the Conrad laboratory has reported initial lead compounds. A related class is the *GPX4 mimetics* — small molecules that catalyze phospholipid hydroperoxide reduction without requiring the natural enzyme, based on ebselen and related organoselenium scaffolds. The class is most likely to find utility as adjunct therapy in acute ferroptotic stress.

4.4 Ferrostatin-1 and Liproxstatin-1: The Lipid-Soluble Radical Traps

The most extensively characterized class of pharmacological anti-ferroptotic compounds is the lipid-soluble radical-trapping antioxidants, exemplified by ferrostatin-1 (Fer-1) and liproxstatin-1 (Lip-1). These compounds were identified through phenotypic screening for inhibitors of erastin- or RSL3-induced cell death. Both operate by donating a hydrogen atom to a lipid peroxyl radical, terminating the chain reaction. Both are lipophilic and partition preferentially into membrane bilayers.

Fer-1 and Lip-1 have been used extensively as chemical-biology probes and have demonstrated ferroptotic rescue in mouse models of acute kidney injury, intracerebral hemorrhage, traumatic brain injury, and several neurodegeneration paradigms. The translational utility is constrained by pharmacokinetic limitations, but the compounds have validated the lipid-soluble radical-trap mechanism as a therapeutic strategy. Second-generation compounds with improved pharmacokinetics are in development.

4.5 The FSP1–CoQ_{10} Parallel Pathway

The 2019 discovery of FSP1 (ferroptosis suppressor protein 1, also called AIFM2) as a GPX4-independent anti-ferroptotic defense substantially revised the field's understanding. FSP1 is a membrane-associated flavoprotein that reduces CoQ_{10} to ubiquinol; ubiquinol then acts as a lipid-soluble radical-trapping antioxidant in membranes, neutralizing lipid peroxyl radicals independently of GPX4. The pathway provides a parallel arm of ferroptotic defense that operates without requiring glutathione, selenium, or NADPH-glutathione regeneration.

The pharmacological implications are significant. *First*, direct CoQ_{10} supplementation provides a potential intervention bypassing the GPX4 axis entirely. CoQ_{10} has a long safety record; clinical trials in neurodegeneration have been generally negative, but the trials predate the FSP1 discovery and were not designed against ferroptotic endpoints. *Second*, FSP1 activators represent a pharmacological target class in early development. *Third*, the FSP1 pathway provides redundancy explaining why GPX4 knockout mice die earlier than would be expected if GPX4 were the sole defense. The conceptual case for combination therapy in the ferroptotic axis is strengthened by the FSP1 discovery.

4.6 The Stockwell Program and the Next Generation

Brent Stockwell at Columbia University has led the most systematic program of ferroptosis pharmacology since the 2012 formal definition of the cell-death modality. The Stockwell program has produced the canonical chemical-biology probes (ferrostatin-1, liproxstatin-1, RSL3, erastin) and has identified multiple new regulators of the ferroptotic pathway. The next-generation Stockwell compounds — targeting GPX4 stabilization, FSP1 activation, and selective labile iron binding — are expected to enter clinical development over the next several years and will likely define the pharmacological landscape of ferroptosis therapy in the late 2020s.

Chapter V

Convergence

Upstream Chelation, Downstream Defense, and Trilogy Integration

5.1 Two Routes to the Same Target

The pharmacological logic of pairing chelation with GPX4 stabilization is identical in form to the dyad strategies of Volumes I and II. Chelation acts upstream by reducing the labile iron flux into Fenton chemistry; GPX4 stabilization acts downstream by preserving the cellular defense against lipid hydroperoxides. The two interventions are mechanistically orthogonal and should compose multiplicatively against the ferroptotic threshold.

The case for combination is strengthened by three considerations. *First*, the upstream-only strategy has failed in the deferiprone trial. *Second*, the downstream-only strategy faces the same threshold problem from the opposite direction. *Third*, the FSP1 discovery has identified a parallel downstream arm whose engagement provides a third dimension of intervention.

5.2 The 4-HNE Adduction Problem (Connection to Volume I)

The principal connection to the ATP synthase axis operates through the 4-HNE adduction problem. 4-HNE, the principal toxic byproduct of lipid peroxidation, is a Michael-addition electrophile that forms covalent adducts with cysteine, histidine, and lysine residues of cellular proteins. The F1 catalytic core of ATP synthase is a preferential target — the β-subunit Cys294, central to the catalytic mechanism, is among the most heavily adducted sites in postmortem AD brain. Ferroptotic activation therefore propagates forward as ATP synthase inactivation; reducing the ferroptotic flux through chelation and GPX4 stabilization preserves ATP synthase function downstream.

The reverse relationship also operates: ATP synthase decline produces mitochondrial ROS elevation, which contributes to the upstream oxidative-stress arm that overwhelms GPX4 capacity. The ATP synthase modulators of Volume I therefore reduce the ferroptotic stress load that the GPX4 axis must contain. The two axes are bidirectionally coupled.

5.3 The NADPH–GSH Cascade (Connection to Volume II)

The connection to the NAD^+ axis operates through the NADPH regeneration cascade. GPX4 consumes GSH to neutralize lipid hydroperoxides, generating GSSG. GSSG is regenerated to GSH by glutathione reductase using NADPH as electron donor. NADPH is regenerated by the pentose phosphate pathway, which depends on $NADP^+$ availability; $NADP^+$ is phosphorylated from NAD^+ by NAD^+ kinase. The NAD^+ pool size therefore sets the upper ceiling on NADPH regeneration, on GSH regeneration, and on sustained GPX4 activity.

NAD^+ depletion (Volume II) propagates forward as ferroptotic vulnerability through this cascade. Restoring NAD^+ through precursor supplementation and CD38 inhibition restores the entire downstream cascade and preserves the GSH supply on which GPX4 depends. The NAD^+ axis is therefore not merely a bioenergetic intervention but also an upstream component of the anti-ferroptotic defense.

5.4 The Microglial Iron–CD38 Loop (Connection to the Collapse Trilogy)

The principal connection to the Collapse Trilogy framework runs through microglial biology. Activated microglia accumulate iron substantially — the Kenkhuis et al. (2023) work documented disease-associated microglia in AD brain as iron-laden, CD38-elevated, and ferroptosis-prone — and this iron-laden microglial population is the principal source of the inflammatory cytokines that drive the homeostatic-to-DAM transition in neighboring microglia. The microglial iron loading itself contributes to ferroptotic stress: the iron-rich microglial population is one of the most ferroptosis-susceptible populations in the aged brain.

The pharmacological implication is that anti-ferroptotic intervention addressed to the microglial population should suppress the microglial ferroptotic arm of the homeostatic collapse loop. This is mechanistically complementary to the NAD^+

precursor/CD38 inhibitor combination (Volume II) and to the ATP synthase modulators (Volume I). The three axes converge on the microglial homeostatic signature from three different upstream interventions.

5.5 The Four-Component Regimen Completed

The composite picture that emerges from Volumes I–III of this series is a coordinated four-component pharmacological regimen for age-associated neurodegeneration:

- *(i)* a direct mitochondrial-function modulator (J-147 class, Volume I §3) that engages the AMPK-mTORC1 adaptive signaling program;
- *(ii)* an upstream oxidative-damage suppressor (AG18051-class NQO2 inhibition, Volume I §4) that protects the bioenergetic machinery;
- *(iii)* an NAD^+ precursor (NR or NMN) paired with a CD38 inhibitor (78c or MK-class, Volume II §3–4) that restores the substrate supply to the OXPHOS-sirtuin-biogenesis system;
- *(iv)* a selective labile-iron chelator paired with a GPX4 stabilizer and supplementary FSP1-CoQ_{10} support (Volume III §3–4), that arrests the ferroptotic-bioenergetic spiral at its terminal substrate.

The regimen addresses, in coordinated combination, the catalytic chokepoint (ATP synthase), the substrate supply (NAD^+), the upstream damage flux (NQO2-derived ROS, iron-Fenton chemistry), and the terminal defense (GPX4, FSP1-CoQ_{10}). The argument advanced is that no single component will produce the clinical benefit that the mechanistic literature predicts; the combination has the potential to produce disease-modifying benefit at a magnitude orthogonal to anything achievable in current clinical practice.

Chapter VI

Translation, Combination Paradigms, and Predictions

6.1 The Post-Deferiprone Clinical Landscape

The 2024 deferiprone Phase II failure has substantially reshaped the clinical-development landscape. The failure was not a failure of the iron-ferroptosis hypothesis; it was a failure of the pan-iron-depletion strategy. The post-deferiprone landscape is characterized by three principal directions. *First*, the development of selective labile-iron chelators that preserve essential iron pools. *Second*, the development of GPX4 stabilizers and FSP1 activators as downstream targets. *Third*, the development of combination strategies that pair modest chelation with downstream defense potentiation.

No clinical trial has yet tested the chelator–GPX4 stabilizer combination, and the next-generation compound classes are not yet at clinical-development readiness. The principal near-term clinical opportunity is the deployment of selenium supplementation and CoQ_{10} supplementation in stratified populations (PSEN1 carriers, low-selenium-status patients, patients with high baseline ferritin) as a low-cost biomarker-stratified preventive intervention.

6.2 Selenium Status as a Biomarker

Plasma selenium concentration is the most pharmacologically tractable biomarker in the ferroptotic axis. It is widely measured, has a clear relationship to GPX4 activity, has a defined sub-saturation range amenable to supplementation, and is largely independent of genetic background. The recommendation is that plasma selenium be measured routinely in patients at risk for AD and PD, and that selenium supplementation be considered for patients with plasma selenium below 100 µg/L. This is a low-cost, low-risk intervention with a clear mechanistic rationale and a defined biomarker target.

The PSEN1 genotype provides a second stratification variable. PSEN1 mutation carriers have impaired LRP8-mediated selenium uptake and may benefit disproportionately from selenium supplementation; the population is rare but well-characterized, and a stratified trial in PSEN1 carriers would provide a high-information experimental test of the LRP8-GPX4 mechanism.

6.3 APOE4 Stratification

The APOE4 allele is associated with elevated brain iron and elevated lipid peroxidation in carriers, providing a second stratification variable. The mechanism is multifactorial: APOE4 carriers have higher hepcidin levels, lower ferroportin activity, and altered lipid handling that elevates membrane PUFA content. APOE4 homozygotes — approximately 2% of the population but substantially overrepresented in AD — have the highest baseline ferroptotic vulnerability and may benefit disproportionately from combined chelation/GPX4 stabilization intervention. A dedicated APOE4-stratified ferroptotic-intervention trial would be a high-value addition to the clinical-development landscape.

6.4 Falsifiable Predictions

Seven predictions follow from the analysis developed above.

Prediction 1 (selective chelation succeeds where pan-depletion failed). A selective labile-iron chelator that reduces the cytosolic labile pool by 30–50% without altering ferritin-bound or functional iron will produce cognitive-trajectory benefit in an AD population, where deferiprone failed.

Prediction 2 (selenium supplementation in low-status carriers). In PSEN1 mutation carriers with plasma selenium below 90 μg/L, selenium supplementation to 120–140 μg/L will produce measurable elevation in CSF GPX4 activity and biomarker-detectable reduction in lipid peroxidation, with cognitive benefit on a 24-month time horizon.

Prediction 3 (CoQ_{10} in FSP1-high tissue). CoQ_{10} supplementation will produce ferroptotic rescue in cellular and animal models in which FSP1 expression is high; in FSP1-low contexts, CoQ_{10} will be ineffective.

Prediction 4 (Combination synergy). Co-administration of a selective labile-iron chelator, a GPX4 stabilizer, and CoQ_{10} in aged APOE4 homozygote AD mice will

produce cognitive and biomarker benefit exceeding any monotherapy by a margin consistent with multiplicative composition.

Prediction 5 (Volume I + Volume III combination). Co-administration of J-147 with a selective labile-iron chelator will produce restoration of ATP synthase activity exceeding either alone, with synergy proportional to baseline 4-HNE adduction of the F1 β-subunit.

Prediction 6 (Volume II + Volume III combination). Co-administration of the NMN/CD38-inhibitor combination with a GPX4 stabilizer will produce ferroptotic rescue exceeding either alone, with synergy proportional to baseline GSH/GSSG ratio.

Prediction 7 (Microglial ferroptotic rescue). Anti-ferroptotic intervention will produce preservation of the microglial homeostatic signature in aged brain, measurable as elevated P2RY12, TMEM119, and SALL1 expression and reduced DAM-signature gene expression.

Chapter VII

Conclusion

The Bioenergetic Pharmacology Series Synthesis

7.1 The Argument in Brief

The argument reduces to seven propositions. *First*, ferroptosis has emerged as one of the principal terminal cell-death modalities in age-associated neurodegeneration and is mechanistically downstream of the bioenergetic decline addressed in Volumes I and II. *Second*, the ferroptotic pathway operates through four interacting molecular systems — the GSH-GPX4 axis, iron-Fenton chemistry, the lipoxygenase enzymatic arm, and the FSP1-CoQ_{10} parallel defense — each of which provides a pharmacological target. *Third*, the iron-compartmentalization strategy (selective chelators replacing the failed pan-depletion strategy of deferiprone) addresses the upstream substrate flux. *Fourth*, the GPX4 stabilization strategy (selenium, small-molecule stabilizers, lipid-soluble radical traps, FSP1 activators, CoQ_{10}) addresses the cellular defense. *Fifth*, the two strategies are mechanistically complementary and should be combined. *Sixth*, the ferroptotic axis is bidirectionally coupled to the ATP synthase axis (4-HNE adduction of F1 subunits) and to the NAD^+ axis (NADPH-GSH regeneration cascade). *Seventh*, the framework generates seven falsifiable predictions and provides stratification strategies (PSEN1 carriage, APOE4 status, plasma selenium) for next-generation clinical trials.

7.2 What the Monograph Does Not Claim

The monograph does not claim that ferroptosis is the sole or dominant cell-death modality in neurodegeneration; the larger framework of the Collapse Trilogy explicitly incorporates apoptotic, necroptotic, autophagic, and senescence-driven mechanisms alongside the ferroptotic. It does not claim that iron chelation is itself a viable therapeutic strategy in AD, given the deferiprone failure; the case advanced is for *next-generation* selective chelation paired with downstream defense potentiation. It does not claim that GPX4 stabilization will succeed clinically; the class is at an early stage of development. And it does not claim to resolve the upstream-versus-downstream question concerning the relationship between ferroptosis and the bioenergetic decline addressed in Volumes I and II.

7.3 The Bioenergetic Pharmacology Series: A Concluding Synthesis

The three volumes of the Bioenergetic Pharmacology series have developed a single coordinated argument across three distinct pharmacological axes. *Volume I* (ATP Synthase) examined the catalytic chokepoint at which the proton-motive force is converted into ATP, and identified J-147 as the direct modulator and AG18051-class NQO2 inhibitors as the upstream protectant. *Volume II* (NAD^+/CD38) examined the substrate-supply problem, and identified NR/NMN precursors paired with 78c/MK-class CD38 inhibitors as the coordinated intervention against both the synthetic deficit and the catabolic surplus. *Volume III* (Iron/GPX4) examined the terminal ferroptotic substrate, and identified selective labile-iron chelation paired with GPX4 stabilization and FSP1-CoQ_{10} support as the coordinated intervention against ferroptotic cell death.

The composite four-component regimen — direct catalytic modulator, upstream protectant, substrate restorer, and terminal defense — operates against the bioenergetic, redox, substrate-supply, and cell-death axes of neurodegeneration in coordinated combination. The pharmacological logic mirrors the logic by which cardiovascular medicine was transformed across the second half of the twentieth century: not a single magic bullet but a coordinated multi-component regimen whose effects compose multiplicatively against the convergent failure modes of the aging system.

The argument advanced across these three volumes is that geroneuroprotection will follow the same trajectory. The four components are now, individually, emerging into clinical view. The combinations have not yet been tested. The work of the next decade is to operationalize them — through stratified clinical trials, biomarker-guided dose individualization, and outcome measures matched to the upstream mechanism of action of the intervention. If that work succeeds, the disease-modifying benefit will not be marginal. It will be transformative.

The Oskar Fischer of his own time recognized that Alzheimer's disease was not a single lesion but an integration of cellular failure modes. The geroneuroprotective pharmacology of our own time is the operationalization of that recognition. The work continues.

References

Ayton, S., Faux, N. G., & Bush, A. I. (2015). Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. *Nature Communications*, 6, 6760.

Ayton, S., Wang, Y., Diouf, I., Schneider, J. A., Brockman, J., Morris, M. C., & Bush, A. I. (2020). Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. *Molecular Psychiatry*, 25(11), 2932–2941.

Bersuker, K., Hendricks, J. M., Li, Z., Magtanong, L., Ford, B., Tang, P. H., Roberts, M. A., Tong, B., Maimone, T. J., Zoncu, R., Bassik, M. C., Nomura, D. K., Dixon, S. J., & Olzmann, J. A. (2019). The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature*, 575(7784), 688–692.

Bush, A. I. (2025). Iron on trial. *Brain*, 148(2), 401–414.

Crapper McLachlan, D. R., Dalton, A. J., Kruck, T. P., Bell, M. Y., Smith, W. L., Kalow, W., & Andrews, D. F. (1991). Intramuscular desferrioxamine in patients with Alzheimer's disease. *Lancet*, 337(8753), 1304–1308.

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B., & Stockwell, B. R. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. *Cell*, 149(5), 1060–1072.

Doll, S., Freitas, F. P., Shah, R., Aldrovandi, M., da Silva, M. C., Ingold, I., Goya Grocin, A., Xavier da Silva, T. N., Panzilius, E., Scheel, C. H., Mourão, A., Buday, K., Sato, M., Wanninger, J., Vignane, T., Mohana, V., Rehberg, M., Flatley, A., Schepers, A., … Conrad, M. (2019). FSP1 is a glutathione-independent ferroptosis suppressor. *Nature*, 575(7784), 693–698.

Duce, J. A., Tsatsanis, A., Cater, M. A., James, S. A., Robb, E., Wikhe, K., Leong, S. L., Perez, K., Johanssen, T., Greenough, M. A., Cho, H. H., Galatis, D., Moir, R. D., Masters, C. L., McLean, C., Tanzi, R. E., Cappai, R., Barnham, K. J., Ciccotosto, G. D., … Bush, A. I. (2010). Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. *Cell*, 142(6), 857–867.

Kagan, V. E., Mao, G., Qu, F., Angeli, J. P. F., Doll, S., Croix, C. S., Dar, H. H., Liu, B., Tyurin, V. A., Ritov, V. B., Kapralov, A. A., Amoscato, A. A., Jiang, J., Anthonymuthu, T., Mohammadyani, D., Yang, Q., Proneth, B., Klein-Seetharaman, J., Watkins, S., & Bayır, H. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. *Nature Chemical Biology*, 13(1), 81–90.

Kenkhuis, B., van Eekeren, M., Parfitt, D. A., Ariyurek, Y., Banerjee, P., Priller, J., van der Weerd, L., & van Roon-Mom, W. M. C. (2023). Iron accumulation induces oxidative stress, while depressing inflammatory polarization in human iPSC-derived microglia. *Stem Cell Reports*, 18(7), 1351–1365.

Maher, P. (2020). The role of ferroptosis in Alzheimer's disease. *Aging*, 12(13), 12943–12944.

Stockwell, B. R., Friedmann Angeli, J. P., Bayır, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., Noel, K., Jiang, X., Linkermann, A., Murphy, M. E., Overholtzer, M., Oyagi, A., Pagnussat, G. C., Park, J., Ran, Q., … Zhang, D. D. (2017). Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. *Cell*, 171(2), 273–285.

Ursini, F., Maiorino, M., Valente, M., Ferri, L., & Gregolin, C. (1982). Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. *Biochimica et Biophysica Acta*, 710(2),

197–211.

Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., Brown, L. M., Girotti, A. W., Cornish, V. W., Schreiber, S. L., & Stockwell, B. R. (2014). Regulation of ferroptotic cancer cell death by GPX4. *Cell*, 156(1–2), 317–331.

Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004). Iron, brain ageing and neurodegenerative disorders. *Nature Reviews Neuroscience*, 5(11), 863–873.